Impact of Synbiotic Intake on Liver Metabolism in Metabolically Healthy Participants and Its Potential Preventive Effect on Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD): A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Impact of Synbiotic Intake on Liver Metabolism in Metabolically Healthy Participants and Its Potential Preventive Effect on Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD) : A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial. / Mantri, Aakash; Köhlmoos, Anika; Schelski, Daniela Stephanie; Seel, Waldemar; Stoffel-Wagner, Birgit; Krawitz, Peter; Stehle, Peter; Holst, Jens Juul; Weber, Bernd; Koban, Leonie; Plassmann, Hilke; Simon, Marie Christine.
In: Nutrients, Vol. 16, No. 9, 1300, 2024.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Impact of Synbiotic Intake on Liver Metabolism in Metabolically Healthy Participants and Its Potential Preventive Effect on Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD)
T2 - A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
AU - Mantri, Aakash
AU - Köhlmoos, Anika
AU - Schelski, Daniela Stephanie
AU - Seel, Waldemar
AU - Stoffel-Wagner, Birgit
AU - Krawitz, Peter
AU - Stehle, Peter
AU - Holst, Jens Juul
AU - Weber, Bernd
AU - Koban, Leonie
AU - Plassmann, Hilke
AU - Simon, Marie Christine
PY - 2024
Y1 - 2024
N2 - Synbiotics modulate the gut microbiome and contribute to the prevention of liver diseases such as metabolic-dysfunction-associated fatty liver disease (MAFLD). This study aimed to evaluate the effect of a randomized, placebo-controlled, double-blinded seven-week intervention trial on the liver metabolism in 117 metabolically healthy male participants. Anthropometric data, blood parameters, and stool samples were analyzed using linear mixed models. After seven weeks of intervention, there was a significant reduction in alanine aminotransferase (ALT) in the synbiotic group compared to the placebo group (-14.92%, CI: -26.60--3.23%, p = 0.013). A stratified analysis according to body fat percentage revealed a significant decrease in ALT (-20.70%, CI: -40.88--0.53%, p = 0.045) in participants with an elevated body fat percentage. Further, a significant change in microbiome composition (1.16, CI: 0.06-2.25, p = 0.039) in this group was found, while the microbial composition remained stable upon intervention in the group with physiological body fat. The 7-week synbiotic intervention reduced ALT levels, especially in participants with an elevated body fat percentage, possibly due to modulation of the gut microbiome. Synbiotic intake may be helpful in delaying the progression of MAFLD and could be used in addition to the recommended lifestyle modification therapy.
AB - Synbiotics modulate the gut microbiome and contribute to the prevention of liver diseases such as metabolic-dysfunction-associated fatty liver disease (MAFLD). This study aimed to evaluate the effect of a randomized, placebo-controlled, double-blinded seven-week intervention trial on the liver metabolism in 117 metabolically healthy male participants. Anthropometric data, blood parameters, and stool samples were analyzed using linear mixed models. After seven weeks of intervention, there was a significant reduction in alanine aminotransferase (ALT) in the synbiotic group compared to the placebo group (-14.92%, CI: -26.60--3.23%, p = 0.013). A stratified analysis according to body fat percentage revealed a significant decrease in ALT (-20.70%, CI: -40.88--0.53%, p = 0.045) in participants with an elevated body fat percentage. Further, a significant change in microbiome composition (1.16, CI: 0.06-2.25, p = 0.039) in this group was found, while the microbial composition remained stable upon intervention in the group with physiological body fat. The 7-week synbiotic intervention reduced ALT levels, especially in participants with an elevated body fat percentage, possibly due to modulation of the gut microbiome. Synbiotic intake may be helpful in delaying the progression of MAFLD and could be used in addition to the recommended lifestyle modification therapy.
KW - ALT
KW - gut–liver axis
KW - MAFLD
KW - metabolic healthy participant
KW - microbiome
KW - prevention
KW - randomized controlled trial
KW - synbiotics
U2 - 10.3390/nu16091300
DO - 10.3390/nu16091300
M3 - Journal article
C2 - 38732547
AN - SCOPUS:85192890527
VL - 16
JO - Nutrients
JF - Nutrients
SN - 2072-6643
IS - 9
M1 - 1300
ER -
ID: 392987041